SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.
Expert analysis of recent trials reveals how gene mutations can guide future high-risk MDS drug development and improve patient selection.
This SOHO expert review from Johns Hopkins (DeZern) synthesizes recent progress in higher-risk MDS including the clinical significance of IPSS-M molecular integration, the VERONA trial failure and its biomarker-driven lessons, and emerging targets including CDC-like kinases and CD123. The review identifies that biomarker-stratified trial design will be essential for future HR-MDS drug development given repeated Phase III failures with broad enrollment criteria.
What the study was
- Study design
- review
- Population
- Higher-risk MDS
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
VERONA failure and biomarker-driven subset signals are directly relevant to HR-MDS pipeline decisions; IPSS-M reclassification is actively changing clinical practice; DeZern (Johns Hopkins) is a key opinion leader; expert synthesis useful for pipeline prioritization in a field with recent late-stage failures.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.